Disc Medicine (NASDAQ:IRON) Sees Large Volume Increase – Here’s Why

Disc Medicine, Inc. (NASDAQ:IRON) saw unusually-strong trading volume on Wednesday. Approximately 1,586,133 shares traded hands during mid-day trading, an increase of 155% from the previous session’s volume of 622,870 shares. The stock last traded at $79.9430 and had previously closed at $79.48.

Trending Headlines about Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Encouraging bitopertin Phase 3 results: Disc Medicine discussed topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), supporting optimism around the drug’s potential in serious hematologic diseases. APOLLO Phase 3 results
• Positive Sentiment: Jefferies raised its price target to $149: The target increase reflects greater confidence in bitopertin following the Phase 3 update and provides a favorable valuation signal for IRON. Jefferies price target increase
• Positive Sentiment: $450 million financing improves financial flexibility: Disc Medicine priced an upsized offering of 6 million shares at $75 each, with an option for underwriters to purchase 900,000 additional shares. The proceeds should fund clinical development, research and potential commercialization of bitopertin, extending the company’s runway.
• Neutral Sentiment: Unusually high options volume points to elevated investor interest and potentially higher volatility, but does not provide a clear directional signal. Unusually high options volume
• Negative Sentiment: Equity dilution is a near-term headwind: Issuing 6 million new shares increases the share count and may pressure the stock around the $75 offering price, even though the capital strengthens the balance sheet. Disc Medicine public offering
• Negative Sentiment: Director selling adds an overhang: Director Kevin Bitterman sold 41,825 shares for approximately $3.35 million across October 19–21, substantially reducing his direct position. The sales were made under a pre-arranged Rule 10b5-1 plan, making them less indicative of current expectations but still adding potential supply. Kevin Bitterman SEC filing

Analysts Set New Price Targets

IRON has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on shares of Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a report on Tuesday. Truist Financial raised their target price on Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen cut Disc Medicine from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. BMO Capital Markets increased their target price on shares of Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Thursday, October 15th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

Disc Medicine Price Performance

The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The business’s 50-day simple moving average is $71.34 and its 200-day simple moving average is $71.54. The stock has a market cap of $2.88 billion, a PE ratio of -11.40 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, research analysts expect that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other Disc Medicine news, Director Kevin Bitterman sold 25,519 shares of Disc Medicine stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $80.23, for a total value of $2,047,389.37. Following the completion of the transaction, the director directly owned 12,991 shares of the company’s stock, valued at approximately $1,042,267.93. The trade was a 66.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jonathan Yu sold 8,796 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the sale, the chief operating officer owned 54,324 shares in the company, valued at approximately $4,515,410.88. The trade was a 13.94% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 173,046 shares of company stock worth $13,591,034. 3.76% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Disc Medicine in the second quarter worth approximately $180,502,000. Wellington Management Group LLP grew its stake in shares of Disc Medicine by 0.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock valued at $127,362,000 after purchasing an additional 5,975 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Disc Medicine by 191.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock valued at $73,280,000 after purchasing an additional 735,300 shares during the last quarter. Opaleye Management Inc. lifted its stake in shares of Disc Medicine by 103.1% in the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after purchasing an additional 434,000 shares during the period. Finally, Jennison Associates LLC boosted its holdings in shares of Disc Medicine by 14.7% in the first quarter. Jennison Associates LLC now owns 610,382 shares of the company’s stock worth $39,028,000 after buying an additional 78,303 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.